Adiposity Clinical Trial
— RESUME-2Official title:
Understanding the Roles of Estradiol and Follicle-stimulating Hormone in Adipocyte Remodeling Following Surgical and Pharmacology-induced Menopause (RESUME-2 Study)
Verified date | November 2022 |
Source | Pennington Biomedical Research Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The overarching aims of this study are to: 1. Characterize the rate of in vivo adipogenesis, and changes in adipose tissue gene and protein expression, in the scABD and scFEM depots of women undergoing surgical menopause (↓E2, ↑FSH). 2. Characterize the rate of in vivo adipogenesis, and changes in adipose tissue gene and protein expression, in the scABD and scFEM depots of women undergoing gonadal suppression (↓E2, ↓FSH).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | November 11, 2022 |
Est. primary completion date | November 11, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 50 Years |
Eligibility | INCLUSION CRITERIA: - Healthy female - Ages 18-50 y - Planning to have either a laparoscopic bilateral oophorectomy or a laparoscopic unilateral oophorectomy (which would result in no remaining ovaries) - Are willing to drink heavy water (2H2O) over an 8-week period - Medically cleared for participation in the study by OB/GYN and Medical Investigator - Are willing to have blood and fat tissue stored for future use EXCLUSION CRITERIA: - Meet either of the following criteria: - Have all 3 of the major menopause-related symptoms [hot flashes, mood swings, insomnia (trouble sleeping)] - Have 2 of the major menopause-related symptom combinations [hot flashes and mood swings, or hot flashes and insomnia (trouble sleeping)] - Unstable weight in the last 3 months [gain or loss >7 lb (or 3.2 kg)] - History of clinically diagnosed diabetes or a fasting blood glucose >126 mg/dL - Chronic use of systemic glucocorticoids, antipsychotic/antidepressant medications, thiazolidinediones and other medications that cause clinically significant weight gain, weight loss or are known to make changes in fat cell number/size * - Previous bariatric surgery (or other surgeries) for obesity or weight loss (< 3 years ago) - Use of over the counter or prescription weight loss products - History of metabolic diseases (other than diabetes) - History of neurological disease - History of cardiovascular disease (or other chronic diseases) - Pregnant, planning to become pregnant, or breastfeeding - Use of hormone replacement therapy - Unwilling to discontinue any form or hormonal therapy (e.g., contraceptives including birth control pills, vaginal ring, injections, implant, or skin patch; hormonal supplements, etc.) upon enrollment (after the Screening Visit). - Inconsistent use of medications listed above will be evaluated and left up to the discretion of the Medical Investigator to evaluate safety. |
Country | Name | City | State |
---|---|---|---|
United States | Pennington Biomedical Research Center | Baton Rouge | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Pennington Biomedical Research Center | University of Alabama at Birmingham, University of Colorado, Denver |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of in vivo adipogenesis (via deuterium-enrichment of adipose tissue DNA) | Deuterium from the deuterium-labeled water is incorporated into the newly-synthesized DNA of newly-formed fat cell precursor cells through cell replication. The latter carry over the label when they become fat cells through differentiation. Enzymatic digestion of the fat tissue isolates the individual cells constituting the fat tissue. Centrifugation of the cell suspension allows the separation of fat cells into a floating layer and a pellet comprised of stromal-vascular cells including the fat cell precursor cells and small fat cells. As the fat cell precursor cells and small adipocytes have the property to attach quickly to plastic surfaces of culture dishes, a brief culturing of the stromal-vascular cells sorts these cells from the remaining cells. Thus, measuring the deuterium-enrichment of DNA from plastic-adherent stromal-vascular cells indicates the rate of in vivo formation of new mature fat cells and pre-adipocytes, a process collectively termed adipogenesis. | Change from baseline in enrichment of DNA of adipose cells with deuterium at 8 weeks | |
Secondary | Size of adipocytes | Fat cell size will be determined using osmium fixation of the lipids and measurement of their diameter with Coulter Counter followed by calculation of fat cell volume. The mean lipid content of fat cells will be calculated by multiplying the fat cell volume by the density of triolein (0.915). | Change from baseline in size of adipocytes at 8 weeks post-surgery | |
Secondary | Number of adipocytes | Fat cell number will be estimated by dividing the volume of adipose tissue depot of interest to the mean fat cell volume or the fat mass of the depot to the mean lipid content in fat cell. | Change from baseline in number of adipocytes at 8 weeks post-surgery | |
Secondary | Body composition (by Dual-energy X-ray Absorptiometry (DXA)) | Fat mass, fat-free mass, and percent body fat will be assessed using a whole-body scanner GE iDXA. | Change from baseline in body composition at 8 weeks post-surgery | |
Secondary | Adipose tissue gene and protein expression | Expression levels of genes and proteins involved in adipocyte expansion and function (ERa, PPAR?2, C/EBPa, aromatase, adiponectin, and LPL), extracellular matrix remodeling and fibrosis (COL6(a1, a2, a3), COL4a1, and TGFß), and inflammation (IL-6 and TNFa) will be assessed. | Changes from baseline in gene and protein expression at 8 weeks post-surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05486338 -
Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy
|
N/A | |
Active, not recruiting |
NCT02558920 -
Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
|
||
Recruiting |
NCT04098679 -
Childhood Adiposity and Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes (CONCEPTT Kids)
|
||
Terminated |
NCT03631680 -
The Role of Estrogen in Adipocyte Remodeling Following Surgical Menopause
|
||
Not yet recruiting |
NCT04096404 -
Gene-based Personalised Diet and Physical Activity Advice on Adiposity Indices Personalised Diet and Physical Activity Advice on Adiposity Indices in University Students
|
N/A | |
Completed |
NCT02975258 -
Adiposity and Airway Inflammation in HIV-Associated Airway Disease
|
N/A | |
Enrolling by invitation |
NCT01971840 -
Effectiveness of a Physical Activity Intervention on Preventing Obesity During the Adiposity Rebound Period.
|
N/A | |
Completed |
NCT02151825 -
Effect of a Synbiotic on the Gut Microbiota and Adiposity-related Markers in Healthy Overweight Subjects
|
N/A | |
Recruiting |
NCT05992688 -
The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)
|
N/A | |
Active, not recruiting |
NCT03575897 -
Serial Assessment of Body Fat Accrual in Very Preterm Infants
|
N/A | |
Completed |
NCT03642223 -
Central and Peripheral Adiposity and Iron Absorption
|
N/A | |
Active, not recruiting |
NCT03542370 -
Umbrella Review of the DASH Dietary Pattern and Cardiometabolic Risk
|
||
Completed |
NCT03898518 -
The Effects of a Jump Rope Exercise Program on Body Composition and Self-efficacy in Obese Adolescent Girls
|
N/A | |
Recruiting |
NCT05324488 -
Diabetes Registry Graz for Biomarker Research
|
||
Completed |
NCT02654535 -
Meta-analyses of Nuts and Risk of Obesity
|
||
Completed |
NCT01922791 -
Nutrition and Pregnancy Intervention Study
|
N/A | |
Recruiting |
NCT02041039 -
REWARD SYSTEM RESPONSES TO FOOD AROMAS
|
||
Completed |
NCT03219125 -
Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women
|
||
Recruiting |
NCT05433688 -
Study on the Performance of Symmcora® Mid-term Suture Versus Novosyn® Suture in Patients Undergoing Robotic Assisted Gastric Bypass Surgery
|
||
Active, not recruiting |
NCT05654051 -
The SLIM LIVER Study
|
Phase 2 |